Q1 2024 13F Holders as of 31 Mar 2024
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
6,717,455
-
Number of holders
-
17
-
Total 13F shares, excl. options
-
1,611,148
-
Shares change
-
+224,304
-
Total reported value, excl. options
-
$5,914,895
-
Value change
-
+$808,610
-
Number of buys
-
12
-
Number of sells
-
-3
-
Price
-
$3.67
Significant Holders of Conduit Pharmaceuticals Inc. - Common Stock, par value $0.0001 per share (CDT) as of Q1 2024
18 filings reported holding CDT - Conduit Pharmaceuticals Inc. - Common Stock, par value $0.0001 per share as of Q1 2024.
Conduit Pharmaceuticals Inc. - Common Stock, par value $0.0001 per share (CDT) has 17 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 1,611,148 shares
of 6,717,455 outstanding shares and own 24% of the company stock.
Largest 10 shareholders include BARCLAYS PLC (804,292 shares), VANGUARD GROUP INC (207,892 shares), BlackRock Inc. (171,582 shares), GEODE CAPITAL MANAGEMENT, LLC (138,937 shares), GOLDMAN SACHS GROUP INC (68,550 shares), MARSHALL WACE, LLP (61,954 shares), Qube Research & Technologies Ltd (40,985 shares), JPMORGAN CHASE & CO (26,830 shares), NORTHERN TRUST CORP (21,786 shares), and Y-Intercept (Hong Kong) Ltd (19,272 shares).
This table shows the top 17 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.